EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial

Ying Zhao, Rulan Griesel iD, Zaayid Omar, Bryony Simmons, Andrew Hill, Gert van Zyl iD, Claire Keene, Gary Maartens iD, Graeme Meintjes

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciad023 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Ying Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine. Hauptthemen laut MEDLINE: Lamivudine, HIV Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Wellcome Trust, University of Cape Town.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dolutegravir concentrations are reduced by efavirenz induction effect necessitating twice-daily dolutegravir dosing when coadministered. Efavirenz induction persists for several weeks after stopping, which could potentially select for dolutegravir resistance if switching occurred with unsuppressed human immunodeficiency virus type 1 (HIV-1) RNA levels and standard dolutegravir dosing. We evaluated the need for a lead-in supplementary dolutegravir dose in adults failing first-line tenofovir-emtricitabine-efavirenz (TEE).

Methods

We conducted a randomized, double-blind, placebo-controlled, phase 2 trial in Khayelitsha, South Africa. Eligible patients had virologic failure (2 consecutive HIV-1 RNA ≥1000 copies/mL) on first-line TEE. Participants were randomly assigned (1:1) to switch to tenofovir-lamivudine-dolutegravir (TLD) with a supplementary 50 mg dolutegravir dose or placebo taken 12 hours later for 14 days. Primary outcome was proportion with HIV-1 RNA <50 copies/mL at week 24. This study was not powered to compare arms.

Results

One hundred thirty participants were randomized (65 to each arm). Median baseline HIV-1 RNA was 4.0 log10 copies/mL and 76% had baseline resistance to both tenofovir and lamivudine. One participant died and 2 were lost to follow-up. At week 24, 55 of 64 (86% [95% confidence interval {CI}: 75%–93%]) in the supplementary dolutegravir arm and 53 of 65 (82% [95% CI: 70%–90%]) in the placebo arm had HIV-1 RNA <50 copies/mL. Grade 3 or 4 adverse events were similar in frequency between arms. None of 6 participants (3 in each arm) eligible for resistance testing by 24 weeks developed dolutegravir resistance.

Conclusions

Our findings do not support the need for initial dolutegravir dose adjustment in patients switching to TLD who failed first-line TEE. Clinical Trials Registration NCT03991013.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LamivudineHIV InfectionsAdultHumansAnti-Retroviral AgentsBenzoxazinesTenofovirEmtricitabineRNADolutegravirAlkynesCyclopropanes

Stichwörter der Autor:innen

HIVantiretroviral therapydolutegravirefavirenzsecond-line

Substanzen

LamivudineAnti-Retroviral AgentsBenzoxazinesTenofovirEmtricitabineRNADolutegravirefavirenzAlkynesCyclopropanes

Autor:innen und Institutionen

  • Department of Medicine.
  • Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine.
  • Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa.
  • LSE Health, London School of Economics and Political Science.
  • Department of Pharmacology and Therapeutics, University of Liverpool, United Kingdom.
  • Division of Medical Virology, Stellenbosch University, South Africa.

ORCID-Profile: Rulan Griesel, Gert van Zyl, Gary Maartens

Förderung

  • NIAID NIH HHS
  • Wellcome Trust
  • University of Cape Town
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health

Zitieren

APA

Zhao, Y., Griesel, R., Omar, Z., Simmons, B., Hill, A., van Zyl, G., Keene, C., Maartens, G., & Meintjes, G. (2023). Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad023

Vancouver

Zhao Y, Griesel R, Omar Z, Simmons B, Hill A, van Zyl G, et al. Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad023

BibTeX
@article{Zhao2023,
  author = {Zhao, Ying and Griesel, Rulan and Omar, Zaayid and Simmons, Bryony and Hill, Andrew and van Zyl, Gert and Keene, Claire and Maartens, Gary and Meintjes, Graeme},
  title = {Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciad023}
}
Kostenlos starten →